Results 111 to 120 of about 6,178 (191)

Once-daily oral deferasirox for the treatment of transfusional iron overload

, 2008
The increasing use of blood transfusions, combined with extended patient survival, has led to an increase in the number of patients at risk of developing transfusional iron overload.
Galanello R, ORIGA, RAFFAELLA
core   +1 more source

Assessing the auditory effects of oral chelation therapy drug Deferasirox in individuals with β‐thalassemia major

World Journal of Otorhinolaryngology-Head and Neck Surgery
Objective Our study aimed to investigate the ototoxicity associated with the iron chelator deferasirox in patients with β‐thalassemia major, who were receiving regular transfusion therapy, along with evaluating the data on audiological tests using ...
Balwinder S. Tiwana, Ankita Aggarwal, Sanjeev Bhagat, Harjinder Singh, Dimple Sahni, Vishav Yadav   +5 more
doaj   +1 more source

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior

Caspian Journal of Internal Medicine, 2017
Background: Cardiac complications due to iron overload are the most common cause of death in patients with thalassemia major. The aim of this study was to compare iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and ...
Shahla Ansari, Azita Azarkeivan, Ghasem Miri-Aliabad, Saeed Yousefian, Tahereh Rostami   +4 more
doaj  

Oktaéderes Ru(III)-deferasirox komplexek szintézise és vizsgálata

, 2018
A ruténium egyes komplexei daganatos sejtekkel szemben jelentős aktivitást mutatnak. A vízben rosszul oldódó deferasirox és dekarboxi-deferasrox vaskelátorok a vas megkötésével, valamint ROS képzés hatására a rákos sejteket pusztíthatják.
Ferenczik, Gergő Tamás
core  

Long-term hematological response in 5q- syndrome after lenalidomide suspension and further improvement by deferasirox.

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The long-term hematological response in a patient with 5q- syndrome after lenalidomide suspension and the further improvement observe while she was receiving deferasirox alone is reported.
Pasquale Niscola
doaj  

FORMULATION AND IN-VITRO EVALUATION OF DEFERASIROX ORO-DISPERSIBLE TABLETS

, 2014
Objective: Deferasirox is a once daily, oral iron chelator approved for treatment of transfusional iron overload in adult and paediatric patients.
Mohiuddin, Mohammed Ghulam, Razzaq, Mohammed Abdul, Mohammed, Salahuddin, Aziz, Mohammed Mohammed   +3 more
core  

Therapeutic role of deferasirox loaded niosomes against aluminium-maltolate induced Alzheimer disease: A study in Swiss albino mice. [PDF]

Indian J Med Res
Sankar G, R I, Umasankar H.
europepmc   +1 more source

Repurposing approved drugs as Pendrin (<i>SLC26A4</i>) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation. [PDF]

Front Pharmacol
Lai J, Zhao D, Wang X, Wang B, Nan J.
europepmc   +1 more source

Sustained Erythroid Response to Eltrombopag in Low-Risk Myelodysplastic Neoplasms With Severe Anemia and Thrombocytopenia: A Case Report. [PDF]

Case Rep Hematol
Di Veroli A, De Gregoris C, Laureana R, Caridi M, Panichi V, Poscente M, Oliva EN, Latagliata R.   +7 more
europepmc   +1 more source

Medication Adherence, Clinical Outcomes, and Health-Related Quality of Life Among Pediatric Patients with β-Thalassemia Major Receiving Iron Chelation Therapy: A Multicenter Study from Punjab, Pakistan. [PDF]

Patient Prefer Adherence
Muneeb A, Inam S, Ali I, Alshehri AA, Siddiq M, Ali S.   +5 more
europepmc   +1 more source